AI Article Synopsis
- Nipah virus (NiV) and Hendra virus (HeV) are dangerous zoonotic viruses that have reappeared in the last decade, prompting research into vaccines.
- A study tested a vaccine made from the HeV attachment glycoprotein and an adjuvant in cats, showing varying levels of immune response among the vaccinated animals.
- All vaccinated cats were protected from disease after being exposed to NiV, demonstrating promising progress for developing a vaccine for humans against these viruses.
Article Abstract
Nipah virus (NiV) and Hendra virus (HeV) are closely related deadly zoonotic paramyxoviruses that have emerged and re-emerged over the last 10 years. In this study, a subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein from HeV (sG(HeV)) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Different amounts of sG(HeV) were employed and sG-induced immunity was examined. Vaccinated animals demonstrated varying levels of NiV-specific Ig systemically and importantly, all vaccinated cats possessed antigen-specific IgA on the mucosa. Upon oronasal challenge with NiV (50,000TCID50), all vaccinated animals were protected from disease although virus was detected on day 21 post-challenge in one animal. The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186147 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2008.05.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!